Traws Pharma Inc.
(NASDAQ:TRAW) shares are trading lower on Monday as the company faces regulatory challenges regarding its influenza treatment program.
The decline follows a recent update indicating that the planned Phase 2a human influenza challenge study for its lead compound, tivoxavir marboxil, has been deferred due to a negative review from the UK's Medicines and Healthcare Products Regulatory Agency.
TRAW Stock Drops After UK Regulator Delays Influenza Trial Traws Pharma announced that its lead compound, tivoxavir marboxil, demonstrated efficacy in animal models but has hit a regulatory snag, delaying its clinical trials.
The company remains committed to developing long-acting antiviral therapies, emphasizing the ongoing public health threat posed by influenza.
